Program
rademikibart
Also written as “CBP-201”, “Rademikibart in prefilled syringe” and “Rademikibart”.
Its studies are mostly in Dermatitis, Atopic · Asthma · Pulmonary Disease, Chronic Obstructive · Nasal Polyps, led by Connect Biopharm.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Connect Biopharm | 102 open or running | phase 3since Nov 6, 2022 | Jun 15, 2020 | Dec 2026phase 2 · NCT07705737 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 15, 2020First study: phase 2 study in Moderate-to-severe Atopic DermatitisFirst studyNCT04444752 · 226 enrolled · United States, Australia, China and more
- Feb 24, 20212 phase 2 studiesNCT04783389, NCT04773678
- Aug 13, 2021Phase 2 study in Moderate-to-severe Atopic DermatitisNCT05017480 · 330 enrolled · China
- Nov 6, 2022Phase 3 study in Dermatitis, AtopicNCT05614817
- Jun 4, 2023Phase 1 study in Healthy Adult SubjectsNCT05917782 · 324 enrolled · China
- Jun 5, 2023Phase 2 study in Dermatitis, AtopicNCT05905133 · 360 enrolled · China
- Apr 3, 20252 phase 2 studiesNCT06940154, NCT06940141
- Jul 10, 2026Phase 2 study in AsthmaNCT07705737 · 40 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in AsthmaNCT07705737
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07705737Asthma · United States | 2 | Recruiting | Dec 2026 | 40 |
| NCT06940154Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 2 | Completed | Jul 30, 2026 | 159 |
| NCT06940141Asthma · United States, Argentina, Australia and more | 2 | Completed | Jul 17, 2026 | 160 |
| NCT05905133Dermatitis, Atopic · China | 2 | Active, not recruiting | Jun 30, 2024 | 360 |
| NCT05917782Healthy Adult Subjects · China | 1 | Completed | Oct 6, 2023 | 324 |
| NCT05614817Dermatitis, Atopic | 3 | Withdrawn | Aug 2024 | 0 |
| NCT05017480Moderate-to-severe Atopic Dermatitis · China | 2 | Completed | Dec 1, 2022 | 330 |
| NCT04783389Chronic Rhinosinusitis With Nasal Polyps · United States, China, Poland and more | 2 | Terminated | Apr 15, 2022 | 40 |
| NCT04773678Moderate to Severe Persistent Asthma · United States, China, Hungary and more | 2 | Completed | Aug 5, 2023 | 322 |
| NCT04444752Moderate-to-severe Atopic Dermatitis · United States, Australia, China and more | 2 | Completed | Jul 28, 2021 | 226 |
How it is read
Names in the registry
- “CBP-201”, 6 entries
- “Rademikibart in prefilled syringe”, 2 entries
- “Rademikibart”, 1 entry
- “Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)”, 1 entry
- “Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)”, 1 entry
Codes read as this program: CBP201.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 4 studies
- Asthma, 3 studies
- Pulmonary Disease, Chronic Obstructive, 1 study
- Nasal Polyps, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.